Wegovy(Semaglutide)

Wegovy (Semaglutide) is a prescription, once-weekly injectable medication developed by Novo Nordisk for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have weight-related health conditions such as high blood pressure, type 2 diabetes, or high cholesterol.

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the effects of the body’s natural appetite-regulating hormone. By slowing gastric emptying and enhancing feelings of fullness, Wegovy helps reduce hunger and calorie intake, supporting significant and sustainable weight loss when used alongside a reduced-calorie diet and regular physical activity.

Key Features:

• Active ingredient: Semaglutide

• Indication: Chronic weight management in adults and certain adolescents (≥12 years) with obesity or overweight and weight-related conditions

• Administration: Subcutaneous injection, once weekly

• Mechanism of Action: GLP-1 receptor agonist that helps regulate appetite and food intake

• Benefits:

  • Proven, clinically significant weight reduction

  • Convenient once-weekly dosing

  • Helps improve metabolic health markers such as blood pressure and cholesterol